I agree that this trial is almost certain to fail, but as I am sure you know the resistance mutatants are normally preexisting in the patient before treatment a

I agree that this trial is almost certain to fail, but as I am sure you know the resistance mutatants are normally preexisting in the patient before treatment and the treatment just selects for the resistant mutants. I think one of our bigger problems with fighting cancer is we only trial new treatments in people on deaths door who have failed everything else. Treatments that would help someone newly diagnosed (the treatments we really want) are just not possible to bring to market.